1.373 makale bulundu

Parkinson Hastalığında BDNF ve GDNF: Klinik Özellikler, Hastalık Kursu ve İlerleme-Bir Sistematik İnceleme ile İlişkililikler.

BDNF and GDNF in Parkinson's Disease: Associations with Clinical Features, Disease Course, and Progression-A Systematic Review.

Węgrzynek-Gallina J, Buczek A, Malkiewicz J, Chmiela T, Gallina T, Hudzińska P, Siuda J.

Mol Neurobiol · 2026-02-16

DOI: 10.1007/s12035-025-05649-zPMID: 41697575

Cognitive function is associated with the progression of non-tremor motor symptoms in Parkinson's disease.

Gibbs MC, D'Souza A, Sotirakis C, Crawford TJ, Antoniades CA.

Front Aging Neurosci · 2026-02-12

DOI: 10.3389/fnagi.2026.1765860PMID: 41767842

The mitogenome mutation repertoire affects progression of Parkinson's Disease.

Matos GB, Santos CSD, Macêdo LCC, Diniz JPDS, Sousa TP, Cavalcante GC, Silva CS, Cruz RLDS, Moura DD, Ribeiro-Dos-Santos A, Santos-Lobato BL, Araújo GS.

Genet Mol Biol · 2026-02-09

DOI: 10.1590/1678-4685-gmb-2025-0098PMID: 41790955

Frankincense motor semptomları iyileştirir ve oksidatif stres, inflamasyon ve apoptotik hücre ölümünü zayıflatarak ve sinir büyüme faktörü gen ekspresyonunu geliştirerek farelerde Paraquat (PQ) kaynaklı Parkinson hastalığının ilerlemesini azaltır.

Frankincense improves motor symptoms and attenuates the progression of Paraquat (PQ)-induced Parkinson's disease in mice by attenuating oxidative stress, inflammation, and apoptotic cell death and improving nerve growth factor gene expression.

Shalikar S, Mashayekhpour MA, Ebrahimi Vosta-Kalaee S, Abouhosseini Tabari M, Hajizadeh Moghaddam A.

IBRO Neurosci Rep · 2026-02-06

DOI: 10.1016/j.ibneur.2026.02.008PMID: 41716729

Serebrovaskülatürdeki bölgeye özgü varyasyonlar Parkinson hastalığında hastalığın ilerlemesinin altında yatan bir durumdur.

Region-specific variations in the cerebrovasculature underlie disease progression in Parkinson's disease.

Dik D, Halliday GM, Sytnyk V, Shepherd CE.

Brain · 2026-02-01

DOI: 10.1093/brain/awaf305PMID: 41285171

Klinik olarak gelişmiş NLRP3 inhibitörü mikroglial transkriptomu modüle eder ve parkinsonizmin ⁇ -sinüklein kaynaklı ilerlemesini hafifletir.

Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism.

Luque M, Matic M, Heras-Garvin A, Amo-Aparicio J, Luk KC, Haindl MT, Khalil M, Skouras DB, Dinarello CA, Stefanova N.

J Neuroinflammation · 2026-01-31

DOI: 10.1186/s12974-026-03716-3PMID: 41620763

Negatif Alfa-Synüklein Tohum Yükseltme Deneyi ile Parkinson Hastalığının Klinik ve Görüntüleme Özellikleri.

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay.

Brooker SM, Pasquini J, Choi SH, Lafontant DE, Fereshtehnejad SM, Zeighami Y, Grillo P, Riboldi GM, Azizi H, Moqadam R, Kang UJ, Nudelman KNH, Siderowf A, Tanner CM, Tropea TF, Foroud T, Chahine LM, Mollenhauer B, Merchant KM, Galasko D, Coffey CS, Dobkin RD, Brown EG, Alcalay RN, Weintraub D, Marek K, Simuni T, Gonzalez-Latapi P, Pavese N, Poston KL, Parkinson's Progression Markers Initiative.

Mov Disord · 2026-01-28

DOI: 10.1002/mds.70197PMID: 41603617

Sporadik ve Genetik Parkinson Hastalığında ⁇ -Synüklein Statüsü ile Dopaminerjik Disfonksiyon ve Subkortikal Atrofinin Dağınıklığı.

Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α-Synuclein Status in Sporadic and Genetic Parkinson's Disease.

Duong MT, Das SR, Khandelwal P, Vizcarra JA, Li Y, Xie L, Yushkevich PA, Shaw LM, Dubroff JG, Parkinson's Progression Markers Initiative, Siderowf A, Wolk DA, Nasrallah IM.

Mov Disord · 2026-01-28

DOI: 10.1002/mds.70186PMID: 41603647

Alkol alımının Parkinson hastalığı riski ve ilerlemesi üzerindeki etkisi: Sistematik bir gözden geçirme ve prospektif çalışmaların doz-yanıt Meta-analizi.

Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.

Hemeda S, Elmadani M, Merzah M, Odeh A, Pintér E, Balás I, Janszky J, Pintér D, Kovács N.

Mov Disord · 2026-01-24

DOI: 10.1002/mds.70200PMID: 41578833

Optimizing Parkinson's disease progression scales using computational methods.

Benesh A, Alcalay RN, Mirelman A, Shamir R.

NPJ Parkinsons Dis · 2026-01-23

DOI: 10.1038/s41531-026-01259-1PMID: 41577682

Parkinson hastalığında uzunlamasına semptom ilerlemesinin manyetoensefalografiye dayalı tahmini.

Magnetoencephalography-based prediction of longitudinal symptom progression in Parkinson's disease.

Waldthaler J, Comarovschii I, Lundqvist D.

NPJ Parkinsons Dis · 2026-01-22

DOI: 10.1038/s41531-025-01240-4PMID: 41571668

Association of a five-metabolite and early-symptom profile with Parkinson's disease and its clinical progression.

Oropeza Valdez JJ, Elizalde-Díaz JP, Antonio OR, -Hernández JL, Adalid-Peralta L, Rodríguez-Violante M, Mandal R, Wishart DS, López-Hernández Y, -Martínez EM.

Sci Rep · 2026-01-21

DOI: 10.1038/s41598-026-36756-zPMID: 41565969